Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Kathy Giacomini, PhD

    SchoolUCSF School of Pharmacy
    Address1550 4th Street, Bldg 19B
    San Francisco CA 94158
    vCardDownload vCard
      Other Positions
      TitleChair, Bioengineering and Therapeutic Sciences

      Collapse Biography 
      Collapse Awards and Honors
      Swedish Academy of Pharmaceutical Scientists2011Scheele Award
      Therapeutic Frontiers Lecture Award2010Therapeutic Frontiers Lecture Award
      Postdoctoral Scholars Association, University of California, San Francisco2009Outstanding Mentor Award
      American Society for Clinical Pharmacology and Therapeutics2009Rawls-Palmer Progress in Medicine Award
      Japan Society for the Promotion of Science2008Invitation Fellowship Program for Research in Japan
      Academy of Pharmaceutical Sciences and Technology, Japan2007International Woman Scientist Award
      Pharmaceutical Sciences World Congress2007Research Achievement Award
      Institute of Medicine of the National Academy of Sciences2006Elected Member
      American Association of Pharmaceutical Scientists2006Distinguished Scientist Award in Drug Metabolism
      American Association of Colleges of Pharmacy2005Paul Dawson Biotechnology Award
      State University of New York at Buffalo2002Distinguished Gerhard Levy Lectureship
      U.S. Food and Drug Administration2002Distinguished Bill Abram's Lectureship
      University of California, San Francisco2002Honored Celebrating Women Faculty
      University of Kentucky2000Guttman Lecturer
      International Pharmaceutical Federation (FIP)1999Scientist of the Year
      University of California, San Francisco1999Recognition Award for Distinguished Achievement of a Filipino at UCSF
      University of California, San Francisco1997Chancellor's Award for the Advancement of Women
      University of California, San Francisco1994Martin Luther King, Jr. Award for the Advancement of Minorities
      National Institutes of Health1992Fogarty International Fellowship
      American Society for Clinical Pharmacology and Therapeutics1990Leon Goldberg Young Investigator Award
      University of California, San Francisco, Academic Senate1985Distinguished Teaching Award
      American Association of University Women1984UCSF Nominee for Recognition Award for Young Scholar
      School of Pharmacy, University of California, San Francisco1983Long Foundation Award for Excellence in Teaching

      Collapse Overview 
      Collapse Overview
      The Giacomini research group focuses on expanding our understanding of membrane transporters. Membrane transporters are of great pharmacological importance, as they play a major role in drug efficacy by regulating drug disposition and distribution. Major questions addressed in the laboratory include: What is the in vivo role of membrane transporters in drug disposition and response? How does genetic variation in membrane transporters affect clinical drug response? What is the endogenous role of membrane transporters? And, what are the structural determinants of specificity?

      As PI of the NIH-funded Pharmacogenomics of Membrane Transporters project, Dr. Kathy Giacomini is leading an effort to determine the clinical implications of specific genetic variants in over 100 membrane transporters. Project ventures, ranging from basic discovery to clinical studies, have demonstrated that common variants of membrane transporters contribute to differences in drug response in ethnically diverse populations. Ultimately, these studies will increase our knowledge of the genetic basis underlying drug response, and will contribute to advancing the era of personalized medicine. Furthermore, our studies will elucidate the genetic mechanisms of decreased drug response and, ultimately, contribute to improving drug design for safe and effective treatments of subgroups of patients who do not respond to standard treatments.

      Research in the laboratory focuses on drugs used in the treatment of diseases associated with metabolic syndrome. We are particularly interested in two key therapeutic agents, allopurinol, first-line medical therapy for gout and high uric acid levels, and the anti-diabetic drug, metformin, one of the world’s most widely prescribed drugs. In particular, our research focuses on discovering functional genetic variants that underlie variation in response to these drugs in large ethnically diverse patient populations. As a co-leader of the international MetGen consortium with over 10,000 patients from Europe and the U.S. on metformin, Giacomini and her collaborators are seeking to discover genetic factors that contribute to poor response to metformin. Importantly, her group is interested in understanding the molecular mechanisms responsible for metformin’s pharmacologic action. For allopurinol, we have discovered that genetic variants in membrane transporters contribute to variation in response to allopurinol. We are now seeking to understand the mechanisms through which the variants act on allopurinol response.

      Finally, Kathy Giacomini and her collaborator, Russ Altman of Stanford University are the Co-PIs of the UCSF–Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI) funded by the Food and Drug Administration (FDA). Established in 2014, the UCSF-Stanford CERSI aims to advance the field of regulatory sciences and improve the development and evaluation of diagnostics, therapeutics and medical devices. The UCSF-Stanford CERSI is the first FDA funded CERSI on the west coast and seeks to address key challenges related to education and research that will advance the discovery and development of medical products.

      Collapse Interests
      Pharmaceutical sciences, pharmacogenomics, pharmacogenetics, membrane transporters, metformin, regulatory sciences, bioengineering, therapeutics.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse NIH Awarded Grants
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21.
        View in: PubMed
      2. Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013 Jul; 94(1):23-6.
        View in: PubMed
      3. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18.
        View in: PubMed
      4. Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011 Oct; 21(10):679-86.
        View in: PubMed
      5. Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K. Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Pharmacotherapy. 2008 Jul; 28(7):821-33.
        View in: PubMed
      6. Cropp CD, Komori T, Shima JE, Urban TJ, Yee SW, More SS, Giacomini KM. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr; 73(4):1151-8.
        View in: PubMed
      7. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
        View in: PubMed
      8. Hayes K, Morgan B, Giacomini K, Dockal S. . Caring for the community. Caring. 1993; 1(12):38-42.
      9. Soles C, Giacomini KM, Roberts SM, Giacomini JC. Soles C, Giacomini KM, Roberts SM, Giacomini JC. A Convenient Method for Repetitive Blood Sampling in the Dog. J. Pharmacol. Meth. 1978; (1):259-261.
      Kathy's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP